Psychostimulants given in adolescence modulate their effects in adulthood using the open field and the wheel-running assays

Brain Research Bulletin

Volumn 82, Issue 3-4, 2010, Pages 208-217

  Yang, P B ^b   Swann, A C ^a   Dafny, N ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Behavior; Methylphenidate; Open field; Wheel running

Indexed keywords

METHYLPHENIDATE; SODIUM CHLORIDE; CENTRAL STIMULANT AGENT;

ANALYSIS OF VARIANCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN DEVELOPMENT; CHEMICAL ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; SENSITIZATION; TREADMILL; ADOLESCENT; ADULT; AGE; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TEST; RUNNING; SPRAGUE DAWLEY RAT;

ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; METHYLPHENIDATE; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; RATS; RATS, SPRAGUE-DAWLEY; RUNNING;

EID: 77953540230     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2010.03.007     Document Type: Article

References (76)

1. Accardo P.P., Blondis T.A. What's all the fuss about Ritalin?. J. Pediatr. 2001, 138:6-9.
2. Algahim M.F., Yang P.B., Wilcox V.T., Burau K.D., Swann A.C., Dafny N. Prolonged methylphenidate treatment alters the behavioral diurnal activity pattern of adult male Sprague Dawley rats. Pharmacol. Biochem. Behav. 2009, 92:93-99.
3. Anckarsater H., Stahlberg O., Larson T., Hakansson C., Jutbland S.B., Niklasson L., Nyden L., Wentz E., Westergren S., Cloninger C.R., Gillberg C., Rostam M. The impact of ADHD and autism spectrum disorders on temperament, character, and personality development. Am. J. Psychiatry 2006, 163:1239-1244.
4. Andersen S.L., Arvaniitaglannis S.A., Pliakas A.M., LeBlance C., Caleron W.A. Altered responsiveness to cocaine in rats exposed to methylphenidate during developmental. Nat. Neurosci. 2002, 51:13-14.
5. Andersen S.L., Teicher M.H. Sex differences in dopamine receptors and their relevance to ADHD. Neurosci. Biobehav. Rev. 2000, 24:137-141.
6. Askenasy E.P., Yang P.B., Tober K.H., Dafny N. Methylphenidate (Ritalin): behavioral studies in the rats. Int. J. Neurosci. 2007, 117:757-794.
7. Baldwin J.S., Daddas M.R. Examining alternative explanations of the covariation of ADHD and anxiety symptoms in children: a community study. J. Abnorm. Child Psychol. 2008, 36:67-79.
8. Barr G.A., Wang S. Behavioral effects of chronic cocaine treatment in the week-old rat pup. Eur. J. Pharmacol. 1993, 233:143-149.
9. Berke J.D., Hyman S.E. Addiction dopamine and the molecular mechanisms of memory. Neurons 2000, 25:515-532.
10. Biederman J., Petty C.R., Wilens T.E., Flaire M.G., Purcell C.H., Mick E., Monuteaux C.M., Faraone S.V. Familial risk analysis of attention deficit hyperactivity disorder and substance use disorder. Am. J. Psychiatry 2008, 165:107-115.
11. Bowman B.P., Kuhn C.M. Age-related differences in the chronic and acute response to cocaine in the rat. Dev. Psychobiol. 1996, 29:597-611.
12. Brandon C.L., Marinelli M., Baker L.K., White F.J. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology 2001, 25:651-661.
13. Brandon C.L., Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Eur. J. Neurosci. 2003, 18:1584-1592.
14. Burton C.L., Nobrega J.N., Fletcher P.J. The effects of adolescent methylphenidate self-administration on responding for a conditioned reward, amphetamine-induced locomotor activity, and neuronal activation. Psychopharmacology (Berl.) 2010, 208:455-468.
15. Butcher S.P., Liptrot J., Aburthnott G.W. Characterization of methylphenidate and nomifensine induced dopamine release in rat striatum using in vivo brain microdialysis. Neurosci. Lett. 1991, 122:245-248.
16. Byrnes J.J., Pritchard G.A., Koff J.M., Miller L.G. Prenatal cocaine exposure: decreased sensitization to cocaine and decreased striatal dopamine transporter binding in offspring. Neuropharmacology 1993, 32:721-723.
17. Carroll K., Rounsaville B. History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Comp. Psychiatry 1993, 34:75-82.
18. Challman T.D., Lipsky J.J. Methylphenidate: its pharmacology and uses. Mayo Clin. Proc. 2000, 75:711-721.
19. Cone E.J. Pharmacokinetics and pharmacodynamics of cocaine. J. Anal. Toxicol. 1995, 19:459-478.
20. Crawford C.A., McDougall S.A., Meier T.L., Collins R.L., Watson J.B. Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinas A and dopamine-stimulated adenylyl cyclase activity in the dorsal striatum. Psychopharmacology 1998, 136:24-33.
21. Crutchley A., Temlett J.A. Methylphenidate (Ritalin) use and abuse. S. Afr. Med. J. 1999, 89:1076-1079.
22. Dafny N., Yang P.B. The role of age genotype, sex and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res. Bull. 2006, 68:393-405.
23. Eckermann K., Beasley A., Yang P., Gaytan D., Swann O., Dafny A.N. Methylphenidate sensitization is modulated by valproate. Life Sci. 2001, 69:47-57.
24. Eichlseder W. Ten years of experience with 1000 hyperactive children in a private practice. Pediatrie 1985, 76:176-181.
25. El-Zein R.A., Abdel-Rahman S.Z., Hay M.J., Lopez M.S., Bondy M.L., Morris D.L., Legator M.S. Cytogenetic effects in children treated with methylphenidate. Cancer Lett. 2005, 230:284-291.
26. Federci M., Geracitano R., Bernardi G., Mercuri N.B. Actions of methylphenidate on dopamine neurons of the ventral midbrain. Biol. Psychiatry 2005, 57:361-365.
27. Fone K.C., Nutt D.J. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr. Opin. Pharmacol. 2005, 5:87-93.
28. Gatley S.J., Volkow N.D., Gifford A.N., Fowler J.S., Dewey S.L., Ding Y.-S., Logan J. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology 1999, 146:93-100.
29. Gaytan O., Lewis C., Swann A., Dafny N. Diurnal differences in amphetamine sensitization. Eur. J. Pharmacol. 1999, 374:1-9.
30. Gaytan O., Yang P., Swann A., Dafny N. Diurnal differences in sensitization to methylphenidate. Brain Res. 2000, 864:24-39.
31. Goldman L., Genel M., Bezman R., Slanetz P. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998, 279:1100-1107.
32. Hechtman L. Assessment and diagnosis of attention deficit/hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am. 2000, 3:481-498.
33. Huttenlocher P.R. Synaptic density in human frontal cortex-developmental changes and effects of aging. Brain Res. 1979, 163:195-205.
34. Izenwasser S., Coy A.E., Ladenheim B., Loeloff R.J., Cadet J.L., Dawn F. Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur. J. Pharmacol. 1999, 373:187-193.
35. Jansiewicz E.M., Newschaffer C.J., Denckla M.B., Mostofsky S.H. Impaired habituation in children with attention deficit hyperactivity disorder. Cogn. Behav. Neurol. 2004, 17:1-8.
36. Kalivas P.W., Churchill L., Klitenick M.A. The circuitry mediating the translation of motivational stimuli into adaptive motor responses. Limbic Motor Circuits and Neuropsychiatry 1993, 237-287. CRC Press, Boca Raton. P.W. Kalivas, C.D. Barnes (Eds.).
37. Kaminer Y. Clinical implications of the relationship between attention-deficit hyperactivity disorder and psychoactive substance use disorders. Am. J. Addict. 1992, 1:257-264.
38. Kollins S.H., MacDonald E.K., Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects. A review. Pharm. Biochem. Behav. 2001, 68:611-627.
39. Kuczenski R., Segal D.S. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J. Neurosci. 2002, 22:7264-7271.
40. Lambert N.M., Hartsongh C.S. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J. Learn. Disabil. 1998, 31:533-544.
41. Lee M.J., Yang P.B., Wilcox V.T., Burau K.D., Swann A.C., Dafny N. Does repetitive Ritalin injection produce long-term effects on SD female adolescent rats?. Neuropharmacology 2009, 57:201-207.
42. LeMoal M., Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol. Rev. 1991, 71:155-234.
43. Levin F.R., Kleber H.D. Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment. Harv. Rev. Psychiatry 1995, 2:246-258.
44. Mirirnne E., Kankaanpag A., Seppala T. Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effect of dopamine D1 and D2 receptor agonists. J. Pharmacol. Exp. Ther. 2001, 298:539-550.
45. Mithani S., Martin-Iverson M.T., Phillips A.G., Fibiger H.C. The effect of haloperidol on amphetamine and methylphenidate induced condition place preferences and locomotor activity. Psychopharmacology (Berl.) 1986, 90:247-252.
46. Nestler E.J. Molecular neurobiology of drug action. Neuropharmacology 1994, 11:77-87.
47. Nestler E.J. Is there a common molecular pathway for addiction?. Nat. Neurosci. 2005, 8:1445-1449.
48. NIDA notes, vol. 18, no. 3, 2003.
49. Parran T.V., Jasinski D.R. Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch. Intern. Med. 1991, 151:781-783.
50. Patrick K.S., Markowitz J.S. Pharmacology of methylphenidate, amphetamine in antiomers, and penoline in attention deficit/hyperactivity disorder. Hum. Psychopharmacol. 1997, 12:527-546.
51. Pierce R.C., Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Rev. 1997, 25:192-216.
52. Quinn R.W. Attention-deficit/hyperactivity disorder and its comorbidities in women and girls: an evolving picture. Curr. Psychiatry Rep. 2008, 10:419-423.
53. Rakie Q. Development of the primate cerebral cortex. Child and Adolescent Psychiatry 1986, Williams and Wilkins, Baltimore. M. Lewis (Ed.).
54. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 1993, 18:247-291.
55. Rosa-Neto P., Lou H.C., Cumming P., Pryds O., Karreback H., Lunding J., Gjedde A. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescent with attention deficit hyperactivity disorder. Neuroimage 2005, 25:868-876.
56. Schenk S., Izenwasser S. Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine. Pharmacol. Biochem. Behav. 2002, 72:651-657.
57. Seeman P., Madras B. Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. Behav. Brain Res. 2002, 130:78-83.
58. Spear L.P., Brake S.C. Periadolescence: age-dependent behavior and psychopharmacological responsivity in rats. Dev. Psychobiol. 1983, 16:83-109.
59. Van Meel C.S., Heslenfeld D.J., Oesterlaan J., Sergeant J.A. Adaptive control deficits in attention-deficit/hyperactivity disorder (ADHD): the role of error processing. Psychiatry Res. 2007, 151:211-220.
60. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 1998, 155:1325-1331.
61. Volkow N.D., Fowler J.S., Wang G.J., Ding Y.S., Gately S.J. The role of dopamine in the therapeutic and reinforcing effect of methylphenidate in human: result from imaging studies. Eur. Neuropsychopharmacol. 2002, 12:557-566.
62. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M. Dopamine in drug abuse and addiction: result from imaging studies and treatment implication. Mol. Psychiatry 2004, 9:557-569.
63. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M., Telang F. Dopamine in drug abuse and addiction: result of imaging studies and treatment implication. Arch. Neurol. 2007, 64:1575-1579.
64. Wang G.J., Volkow N.D., Hitzemann R.J., Wong C., Angrist B., Burr G., Pascani K., Pappas N., Liu A., Cooper T., Lieberman J.A. Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur. Addict. Res. 1997, 41:49-54.
65. White F.J., Kalivas P.W. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend. 1998, 51:141-153.
66. Wilens T., Biederman J., Spencer T., Frances R. Comorbidity of attention deficit hyperactivity and psychoactive substance use disorders. Hosp. Community Psychiatry 1994, 45:421-435.
67. Wilens T.E., Faraone S.V., Biederman J., Gunawardoene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003, 111:179-185.
68. Yang P., Beasley A., Swann A., Dafny N. Valproate modulates the expression of methylphenidate (Ritalin) sensitization. Brain Res. 2000, 874:216-220.
69. Yang P.B., Amini B., Swann A.C., Dafny N. Strain differences in the behavioral responses of male rats to chronically administered methylphenidate. Brain Res. 2003, 971:139-152.
70. Yang P.B., Swann A.C., Dafny N. Chronic pretreatment with methylphenidate induces cross-sensitization with amphetamine. Life Sci. 2003, 73:2899-2911.
71. Yang P.B., Swann A.C., Dafny N. Acute and chronic methylphenidate dose-response assessment on three different male rat strains. Brain Res. Bull. 2006, 71:301-310.
72. Yang P.B., Swann A.C., Dafny N. Chronic methylphenidate modulates locomotor activity and sensory evoked responses in the VTA and NAc of freely behaving rats. Neuropharmacology 2006, 51:546-556.
73. Yang P.B., Swann A.C., Dafny N. Sensory evoked potentials recording from the VTA, NAc, PFC and CN, and locomotor activity are modulated in dose response characteristics by methylphenidate. Brain Res. 2006, 1073:164-174.
74. Yang P.B, Swann A.C., Dafny N. Chronic administration of methylphenidate produces neurophysiological and behavioral sensitization. Brain Res. 2007, 1145:66-80.
75. Yang P.B., Swann A.C., Dafny N. Methylphenidate treated at the test cage-dose dependent sensitization or tolerance depends on the behavioral assay used. Crit. Rev. Neurosci. 2007, 19:59-77.
76. Zito J.M., Safer D.J., dosReis S., Gardner J.F., Boles M., Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. Am. Med. Assoc. 2000, 283:1025-1030.